Company intelligence / Profile preview

Exoneural Network

Sundbyberg/Solna, Swedenottobock.com ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

The company’s main product, the Exopulse Mollii Suit, has been commercially available in Europe since late 2012. It targets spasticity and motor impairment in patients with neurological conditions such as cerebral palsy, stroke, and multiple sclerosis. Clinical results are not detailed in public sources but the device has achieved regulatory approval for sale as a medical device.

Therapeutic areas: Neurology
Modalities: DeviceWearable medical deviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Ottobock SE & Co. KGaA (acquirer/strategic partner)

Beyond the preview

Go deeper on Exoneural Network.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exoneural Network.

Explore the full profile